Aseptic Fill Finish
We provide custom live virus and fill/finish services
CDMO for Biotherapeutics and Vaccines
With aseptic filling operations in the U.S. and Europe, ABL provides the flexibility and logistical responsiveness needed to support global clinical trials. Meeting demanding timelines is what we do—whether a comprehensive GMP production program or a standalone drug product fill—we integrate vialing, inspection, labeling, testing, storage and distribution activities for the provision of clinical trial materials.
ABL stands shoulder-to-shoulder with our clients as a catalyst for life-changing innovations. We’ve supported fill/finish projects for SARS-CoV-2 (COVID-19) vaccine candidates—and are available for new projects NOW.
ABL has filled hundreds of GMP gene therapies, vaccines, oncolytic vectors and other immunotherapies at facilities located in the U.S. and Europe
Global viral vector and protein fill/finish services:
Operational excellence meets speed and flexibility
Global viral vector expertise coupled with state-of-the-art facilities
ABL provides aseptic drug fill/finish services using a fully automated Flexicon FPC50W filling machine installed within a Grade A Restricted Access barrier (RABS) system. A bracket approach is applied across the qualified fill configurations to a maximum lot sizeof 3000 vials, where one configuration of each size/component material of construction is re-qualified every six months.